NCT06072001 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis | Biotech Hunter

Enrollment

558

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions

PainPain SyndromePain, ChronicChronic PainChronic Pain SyndromeNeuropathic PainCentral Neuropathic PainParaplegiaMultiple SclerosisStrokePhantom Limb Syndrome With PainPhantom PainTraumatic Brain Injury

Interventions

DRUG

Adezunap (AP707)

Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.

DRUG

Placebo

Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.

Trial Locations (1)

81675

RECRUITING

Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich